Fig. 1 (➚): http://www.cochrane.org/about-us/history/our-logo%23files.
Fig. 2 (➚): Mulrow, C. D., «Rationale for systematic reviews», British Medical Journal, vol. 309, n.° 6954, 3 de septiembre de 1994, págs. 597-599. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2541393/?page=1.
Fig. 3 (➚): «Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation», NICE, 2006. Disponible en http://www.nice.org.uk/nicemediaflive/11700/34991/34991.pdf.
Fig. 4 (➚): http://www.prescrire.org/editoriaux/EDI33693.pdf.
Fig. 5 (➚).
Fig. 6 (➚): Carpenter, D., Reputation and Power: Organitational Image and Pharmaceutical Regulation at the FDA, Princeton University Press, 2010.
Fig. 7 (➚): Schwartz, L. M., Woloshin, S., Welch, H. G., «Using a Drug Tacts Box to Communicate Drug Benefits and Harms Two Randomized Trials», Annals of Internal Medicine, vol. 150, n.° 8, 21 de abril de 2009, págs. 516-527. Disponible en http://dartmed.dartmouth.edu/spring08/pdf/ disc_drugs_we/lunesta_box.pdf.
Fig. 8 (➚): http://www.lunesta.com/PostedApproved LabelingText.pdf.
Fig. 9 (➚): Lurie, P., Wolfe, S. M., «Misleading data analyses in salmeterol (SMART) study», The Lancet, vol. 366, n.° 9493, octubre de 2005, págs. 1261-1262.
Fig. 10 (➚).
Fig. 11 (➚): Rothwell, PM., «Subgroup analysis in randomised controlled trials: importance, indications, and interpretation», The Lancet, vol. 365, n.° 9454, 2005, págs. 176-186. Disponible en http://apps.who.int/rhl/Lancet_365-9454.pdf.
Fig. 12 (➚): Moyniham, R., «The making of disease: female sexual dysfunction», British Medical Journal, vol. 326, n.° 7379, 2003, págs. 45-47. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1124933/table/TNOX95f06b0.0X98eca30/.
Fig. 13 (➚): 15 de agosto de 2012, http://uk.finance.yahoo.com/echarts?s=GSK.L#symbol=GSK.L;range=1y.